First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

233

Participants

Timeline

Start Date

October 19, 2016

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2020

Conditions

Cancer, Solid Tumor

Interventions

DRUG

IBI308

DRUG

IBI308\Cisplatinum\Pemetrexed

DRUG

IBI308\cisplatin\gemcitabine

DRUG

IBI308\oxaliplatin\capecitabine

DRUG

IBI308\etoposide\cisplatin

DRUG

IBI308\irinotecan\5-FU

Trial Locations (1)

The fifth medical center of the PLA general hospital, Beijing

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT02937116 - First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter